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Abstract: Alopecia areata (AA) is a common cause of non-scarring alopecia characterized by patchy hair loss. AA is difficult to treat
because of its chronic and inflammatory nature. The aim of the present study was to investigate the effect of low-dose systemic
corticosteroids in the treatment of AA.
Fifteen patients with AA were included in this study. Systemic prednisolone 10-15 mg/day on 2 consecutive days per week for 6
months was administered. Fourteen patients (93.3%) had patchy alopecia areata. One patient (6.3%) had alopecia universalis. Seven
(46.7%) patients showed complete healing, 5 (33.3%) showed partial response and 3 (20%) did not respond to treatment.
Low-dose intermittant corticosteroid therapy may be a successful and well tolerated treatment option in AA and also in patients with
alopecia totalis and universalis.
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Introduction

Materials and Methods

Alopecia areata (AA) is the most common cause of
localized, nonscarring alopecia affecting both children and
adults (1). The incidence is estimated to be 0.05- 0.1%
and it affects men and women equally (2,3). Although the
pathogenesis is not exactly clear, there is increasing
evidence that autoimmunity is the underlying mechanism
(2). In addition, genetic factors and stress have an
important role in the pathogenesis (3). Topical,
intralesional or systemic corticosteroids, PUVA therapy,
cryotherapy, anthralin, minoxidil, topical immunotherapy
and cyclosporine are the treatment approaches that
induce remissions. The therapeutic effects of most of the
treatments are due to an immunomodulatory mechanism
(2). Among these treatment alternatives systemic
corticosteroids have been shown to be effective, but there
are many side effects. To avoid these side effects, in this
study we decided to use low-dose systemic corticosteroid
therapy.

Fifteen patients attending the Kirikkale University
School of Medicine Department of Dermatology were
included in this prospective study. Before inclusion in the
study a complete physical examination, laboratory
investigation including complete blood count, serum
electrolytes, chest X-ray, renal and hepatic function tests
and screening for autoantibodies were performed.
Patients with contraindications to corticosteroid therapy
such as diabetes mellitus, peptic ulcer and acute or
chronic infection were not included in the study. The
treatment schedule consisted of prednisolone 15 mg/day
for 2 consecutive days for patients over 15 years of age
and 10 mg for patients under 15 years of age. The
dosage was kept the same for 6 months. During the
study all other treatment modalities were withheld.
Patients were seen monthly for the efficacy and side
effects of the drug. Complete healing was defined as
regrowth of hair in all the patches. Partial response was
defined as beginning of regrowth of hair with/without
55

The Efficacy of Intermittant Low-Dose Systemic Corticosteroid in the Treatment of Alopecia Areata

light pull positivity and no response as no regrowth of
hair and also progression of hair loss.

Results

autoimmune disease in his family. Their ages ranged
between 4 and 58 years (median 20). The duration of the
disease varied from 1 month to 84 months (median 5).
Fourteen patients (93.3%) had patchy AA. The extent of
involvement ranged from 0 to 40% in 12 patients and
>40% in 2 patients. One patient (6.3%) had alopecia
universalis (AU). Eight (53.3%) patients had the active
disease whereas 7 (46.7%) of them were stable. The
duration of the therapy was 6 months.

Fifteen patients (7 men and 8 women) were
evaluated. Only 1 patient (6.3%) had a history of

Seven (46.7%) patients showed complete healing
(Figures 1 and 2), while 5 (33.3%) of the 15 patients

Statistical Analysis
The results of the study were statistically analyzed by
using the SPSS 10.0 program (Windows, Microsoft,
USA).

Figure 1. Patient (15) before receiving treatment.

Figure 2. Patient after receiving treatment.

56

A. B‹ROL, E. ERKEK, F. TUNCEZ, G. SAYLAM KURT‹PEK, Y. BA⁄CI, M. KOÇAK

showed regrowth of hair in AA lesions and light pull was
also positive (partial remission). Three (20%) of the
patients did not respond to treatment (Table). Overall
healing (complete healing and partial response) was 80%.
There was 1 patient with universal type AA who showed
complete healing after the therapy and did not show
relapse 4 months after cessation of the therapy. After
using a non-parametric Mann-Whitney U test, the healing
did not reveal statistically significant differences according
to disease activity (P = 0.446) and chronicity of the
disease (P = 0.233).

Discussion
It is well known that the clinical course of AA is
extremely variable, showing frequent relapses (4). The
response of alopecia totalis (AT) and AU to treatment is
especially disappointing. Muller and Winkelmann reported
that there is a great tendency for regrowth of hair in
patients with patchy AA except in cases of AU and AT (5).
Therefore, the side effects and benefits of the treatment
must be well thought through. PUVA therapy, anthralin,
minoxidil, topical immunotherapy, cyclosporine and

corticosteroids are typical treatment approaches (6). By
exerting an immunosuppressive effect, corticosteroids
can promote the regrowth of hair in AA (6).
Corticosteroids can be used by topical, intramuscular,
intralesional or oral routes (7). Intralesional
corticosteroid therapy is an effective alternative,
especially in patients with a few patches (4), whereas
systemic steroids are appropriate for rapidly progressive
or extensive forms of AA (7).
Alabdulkareem et al. reported the efficiency of oral
steroid therapy in patients with severe AA (8). They
treated 18 patients with AT and AU at a dose ranging
from 15 to 40 mg/day. They reported satisfactory hair
growth in 38.9% of the patients, but in all of these
patients hair fall occurred after the discontinuation of
therapy.
Seiter et al. used high-dose pulse corticosteroid
therapy in AA (2). They treated 30 patients with
intravenous methylprednisolone on 3 consecutive days at
4-week intervals for at least 3 courses and reported that
they observed no effect in patients with ophiasic AA, AT,
AU, whereas 67% of their patients with AA plurifocalis

Table. Results of systemic corticosteroid therapy in 15 patients with AA.
No.

Type

Age/sex

No. of
patches

Ophiasis

Disease
activity

Duration of
disease (months)

Results

1

AA

13/F

2

no

2

AA

22/F

1

no

3

AA

35/F

2

4

AA

32/F

3

5

AA

11/M

6

AA

24/F

7

AA

23/M

8

AA

58/M

Current status

P

1

NR

P

96

PR

no

P

1

NR

no

P

6

PR

10

no

P

1.5

CR

No activation after 4 months

1

no

S

12

CR

Activation at 4 months

1

no

P

2

CR

Activation at 3 months

15

yes

S

60

NR

9

AA

20/F

4

no

S

96

PR

10

AA

4/M

4

no

S

1

PR

11

AA

12/M

10

yes

S

7

CR

No activation after 14 months

12

AA

22/M

10

no

S

5

CR

No activation after 12 months

13

AA

17/F

2

no

P

9

PR

14

AU

10/F

(-)

(-)

S

72

CR

No activation after 16 months

15

AA

5.5/M

8

(-)

P

5

CR

Activation after 5 months

AA: Alopecia areata, AU: Alopecia universalis, P: Progressive, S: Stable
NR: No response, PR: Partial response, CR: Complete response
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showed 50% hair regrowth (2). In patients with
plurifocal AA they observed more than 50% hair
regrowth. They also observed that patients suffering
from a long-term form of the disease responded better
than patients treated during their first episode (2).
In our study 7 (46.7%) patients showed complete
healing, and 5 (33.3%) showed regrowth of hair in AA
lesions and light pull positivity. Three (20%) of the
patients did not respond to treatment. Overall healing
(complete healing and partial response) was 80% (Table)
We did not observe any difference in the response rate
according to disease chronicity. Patients having the first
episode and patients suffering from AA for many years
responded to low-dose systemic steroid therapy. We
observed complete healing in a patient with AU. She had
suffered from AU for 6 years and had used many
different treatment alternatives without success. In
contrast to Alabdulkareem et al., 4 of the patients who
showed complete healing did not experience hair fall after
many months, and they remain in remission (Table).

The low dose corticosteroid therapy was well
tolerated in our study, and major side effects did not
occur. It would be better to compare the efficacy with a
placebo, but it is hard to accomplish this.
In conclusion, low-dose intermittant corticosteroid
therapy may be a successful and well-tolerated treatment
option in patients with AA, AT and AU.
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